Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone-receptor positive, node-negative early breast cancer: final results of the randomized phase III Femara versus Anastrozole Clinical Evaluation (FACE) trial. J Clin Oncol 2017; 35: 1041-1048.

Published: 28th November 2017

Authors: Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K et al.


Some 4136 women were included. At five years, both disease-free survival (84.9 per cent for letrozole and 82.9 per cent for anastrozole) and overall survival (89.9 and 89.2, respectively) were similar.

Pubmed Link

Your comments